Novel Small Molecule Inhibitors of Cancer Stem Cell Signaling Pathways

Danysh Abetov, Zhanar Mustapova, Timur Saliev, Denis Bulanin, Kanat Batyrbekov, Charles P. Gilman

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The main aim of oncologists worldwide is to understand and then intervene in the primary tumor initiation and propagation mechanisms. This is essential to allow targeted elimination of cancer cells without altering normal mitotic cells. Currently, there are two main rival theories describing the process of tumorigenesis. According to the Stochastic Model, potentially any cell, once defunct, is capable of initiating carcinogenesis. Alternatively the Cancer Stem Cell (CSC) Model posits that only a small fraction of undifferentiated tumor cells are capable of triggering carcinogenesis. Like healthy stem cells, CSCs are also characterized by a capacity for self-renewal and the ability to generate differentiated progeny, possibly mediating treatment resistance, thus leading to tumor recurrence and metastasis. Moreover, molecular signaling profiles are similar between CSCs and normal stem cells, including Wnt, Notch and Hedgehog pathways. Therefore, development of novel chemotherapeutic agents and proteins (e.g., enzymes and antibodies) specifically targeting CSCs are attractive pharmaceutical candidates. This article describes small molecule inhibitors of stem cell pathways Wnt, Notch and Hedgehog, and their recent chemotherapy clinical trials.

Original languageEnglish
Pages (from-to)909-918
Number of pages10
JournalStem Cell Reviews and Reports
Volume11
Issue number6
DOIs
Publication statusPublished - Dec 1 2015

Fingerprint

Neoplastic Stem Cells
Carcinogenesis
Stem Cells
Neoplasms
Wnt Signaling Pathway
Clinical Trials
Neoplasm Metastasis
Recurrence
Drug Therapy
Antibodies
Enzymes
Pharmaceutical Preparations
Proteins
Therapeutics

Keywords

  • Cancer
  • Hedgehog
  • Inhibitor
  • Notch
  • Signaling pathway
  • Stem cells
  • Wnt

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology

Cite this

Novel Small Molecule Inhibitors of Cancer Stem Cell Signaling Pathways. / Abetov, Danysh; Mustapova, Zhanar; Saliev, Timur; Bulanin, Denis; Batyrbekov, Kanat; Gilman, Charles P.

In: Stem Cell Reviews and Reports, Vol. 11, No. 6, 01.12.2015, p. 909-918.

Research output: Contribution to journalArticle

Abetov, Danysh ; Mustapova, Zhanar ; Saliev, Timur ; Bulanin, Denis ; Batyrbekov, Kanat ; Gilman, Charles P. / Novel Small Molecule Inhibitors of Cancer Stem Cell Signaling Pathways. In: Stem Cell Reviews and Reports. 2015 ; Vol. 11, No. 6. pp. 909-918.
@article{e36296ce9f9d44be92ac081ecc84f76e,
title = "Novel Small Molecule Inhibitors of Cancer Stem Cell Signaling Pathways",
abstract = "The main aim of oncologists worldwide is to understand and then intervene in the primary tumor initiation and propagation mechanisms. This is essential to allow targeted elimination of cancer cells without altering normal mitotic cells. Currently, there are two main rival theories describing the process of tumorigenesis. According to the Stochastic Model, potentially any cell, once defunct, is capable of initiating carcinogenesis. Alternatively the Cancer Stem Cell (CSC) Model posits that only a small fraction of undifferentiated tumor cells are capable of triggering carcinogenesis. Like healthy stem cells, CSCs are also characterized by a capacity for self-renewal and the ability to generate differentiated progeny, possibly mediating treatment resistance, thus leading to tumor recurrence and metastasis. Moreover, molecular signaling profiles are similar between CSCs and normal stem cells, including Wnt, Notch and Hedgehog pathways. Therefore, development of novel chemotherapeutic agents and proteins (e.g., enzymes and antibodies) specifically targeting CSCs are attractive pharmaceutical candidates. This article describes small molecule inhibitors of stem cell pathways Wnt, Notch and Hedgehog, and their recent chemotherapy clinical trials.",
keywords = "Cancer, Hedgehog, Inhibitor, Notch, Signaling pathway, Stem cells, Wnt",
author = "Danysh Abetov and Zhanar Mustapova and Timur Saliev and Denis Bulanin and Kanat Batyrbekov and Gilman, {Charles P.}",
year = "2015",
month = "12",
day = "1",
doi = "10.1007/s12015-015-9612-x",
language = "English",
volume = "11",
pages = "909--918",
journal = "Stem Cell Reviews",
issn = "1550-8943",
publisher = "Humana Press",
number = "6",

}

TY - JOUR

T1 - Novel Small Molecule Inhibitors of Cancer Stem Cell Signaling Pathways

AU - Abetov, Danysh

AU - Mustapova, Zhanar

AU - Saliev, Timur

AU - Bulanin, Denis

AU - Batyrbekov, Kanat

AU - Gilman, Charles P.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - The main aim of oncologists worldwide is to understand and then intervene in the primary tumor initiation and propagation mechanisms. This is essential to allow targeted elimination of cancer cells without altering normal mitotic cells. Currently, there are two main rival theories describing the process of tumorigenesis. According to the Stochastic Model, potentially any cell, once defunct, is capable of initiating carcinogenesis. Alternatively the Cancer Stem Cell (CSC) Model posits that only a small fraction of undifferentiated tumor cells are capable of triggering carcinogenesis. Like healthy stem cells, CSCs are also characterized by a capacity for self-renewal and the ability to generate differentiated progeny, possibly mediating treatment resistance, thus leading to tumor recurrence and metastasis. Moreover, molecular signaling profiles are similar between CSCs and normal stem cells, including Wnt, Notch and Hedgehog pathways. Therefore, development of novel chemotherapeutic agents and proteins (e.g., enzymes and antibodies) specifically targeting CSCs are attractive pharmaceutical candidates. This article describes small molecule inhibitors of stem cell pathways Wnt, Notch and Hedgehog, and their recent chemotherapy clinical trials.

AB - The main aim of oncologists worldwide is to understand and then intervene in the primary tumor initiation and propagation mechanisms. This is essential to allow targeted elimination of cancer cells without altering normal mitotic cells. Currently, there are two main rival theories describing the process of tumorigenesis. According to the Stochastic Model, potentially any cell, once defunct, is capable of initiating carcinogenesis. Alternatively the Cancer Stem Cell (CSC) Model posits that only a small fraction of undifferentiated tumor cells are capable of triggering carcinogenesis. Like healthy stem cells, CSCs are also characterized by a capacity for self-renewal and the ability to generate differentiated progeny, possibly mediating treatment resistance, thus leading to tumor recurrence and metastasis. Moreover, molecular signaling profiles are similar between CSCs and normal stem cells, including Wnt, Notch and Hedgehog pathways. Therefore, development of novel chemotherapeutic agents and proteins (e.g., enzymes and antibodies) specifically targeting CSCs are attractive pharmaceutical candidates. This article describes small molecule inhibitors of stem cell pathways Wnt, Notch and Hedgehog, and their recent chemotherapy clinical trials.

KW - Cancer

KW - Hedgehog

KW - Inhibitor

KW - Notch

KW - Signaling pathway

KW - Stem cells

KW - Wnt

UR - http://www.scopus.com/inward/record.url?scp=84947612337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947612337&partnerID=8YFLogxK

U2 - 10.1007/s12015-015-9612-x

DO - 10.1007/s12015-015-9612-x

M3 - Article

C2 - 26210995

AN - SCOPUS:84947612337

VL - 11

SP - 909

EP - 918

JO - Stem Cell Reviews

JF - Stem Cell Reviews

SN - 1550-8943

IS - 6

ER -